Albert J. and Judith A. Dunlap Cancer Center at Mayo Clinic Health ...

More documents

Recommendations

Info

o Research/Clinical Trials o Support Groups • MCHS Cancer Registry o Annual Analytic Case Report o The Function of the Mayo Clinic Health System Cancer Registry o 2011 Analytic Cases by Site, Gender and Stage • Contact Information o Cancer Committee • Commission on Cancer (CoC) Survey: Spring 2013 • 2012 Membership Breast Cancer Outcome Analysis & Comparative Data Report — 2012 The American College of Surgeons’ Commission on Cancer (CoC) and National Accreditation Program for Breast Centers (NAPBC) requires annual performance rates to be reported for six quality measures identified by the NAPBC. Performance and outcomes for these measures are evaluated annually by Mayo Clinic Health System in Eau Claire and breast program leadership. Breast cancer data evaluated for this report is from the Mayo Clinic Health System in Eau Claire Cancer Registry’s 2011 analytic caseload. 1. Basic epidemiology. In 2012, it is estimated that among U.S. women there will be 226,870 new cases of invasive breast cancer (includes new cases of primary breast cancer among survivors, but not recurrence of original breast cancer among survivors). Also, there will be 63,300 new cases of in situ breast cancer (includes ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS), of which about 85 percent will be DCIS. DCIS is a noninvasive breast cancer, and LCIS is a condition that increases the risk of invasive breast cancer. There will be 39,510 women who die of breast cancer. 2. Local epidemiology as to cases within our group. Within 2011, Mayo Clinic Health System in Eau Claire diagnosed and/or provided first-course treatments, often referred to as the analytic caseload to 127 breast patients per the Mayo Clinic Health System in Eau Claire Cancer Registry. The most commonly used method of disease distribution for studies, and in compliance with national guidelines, is the American Joint Committee on Cancer (AJCC) staging, the process that describes the extent or severity of an individual’s cancer based on the extent of the original (primary) and the extent of spread in the body. The 2011 breakdown is as follows: Mayo Clinic Health System in Eau Claire 2011 Analytic Breast Cases by AJCC Stage AJCC Stage TOTAL 0 I II III IV UNK N/A BREAST 127 21 53 33 10 5 3 2 The stage at which the cancer is diagnosed is the best predictor of a woman’s chance of surviving the disease. Early stage, Stage 0–II requires less aggressive, life-interrupting treatments to ensure surviving the diagnosis. Twenty-one cases were Stage 0, 53 cases were Stage I and 33 cases were Stage II. Thus, over 80 percent of the
cases were detected at a highly curable stage. This high percent of early stage cases is also a marker of the clinic’s efforts to promote screening and accuracy of early detection methods such as mammography. 3. Quality of breast cancer care at Mayo Clinic Health System in Eau Claire. We reviewed 80 consecutive cases diagnosed and treated by our group in 2010–2011. They were reviewed for the care they received and how they matched up to recognized measures of high-quality breast cancer care. The following summarizes this review. A. The pattern of care in the CP3R data reports — These reports track the long-term trends in the group’s efforts in key survival enhancing measures. These are national measures and felt by many groups, including the ACS CoC, NCCN, ASCO and others, to demonstrate the quality of a group’s cancer program. Cancer Program Practice Profile Reports (CP 3 R) for Breast Cancers Diagnosed 2004 - 2010 Mayo Clinic Health System, Eau Claire, Wis. FACILITY SELECTION ALL MEASURES SUMMARY THIS MEASURE SUMMARY Combination chemotherapy is considered or administered within four months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage II or III hormone receptor negative breast cancer. [MAC] Diagnosis Year: 2010 (Last Update: Dec 10, 2012 11:12:16 PM CST) Perf. Rate 95% CI Cases #Prog. My Cancer Program 100 % (100 - 100) 7 My State (WI) 98.2 % (96.6 - 99.8) 271 32 My ACS Division (Mid-West) 97.1 % (95.8 - 98.4) 654 69 My Census Region (Greatlakes) 92.9 % (91.9 - 93.9) 2482 253 My CoC Program Type (COMP) 91.9 % (91.3 - 92.5) 6821 560 All CoC Approved Programs (ALL) 90.7 % (90.2 - 91.2) 13670 1283 Interpreting this table: The estimated performance rates shown in this table provide your cancer program with an indication of the proportion of women under 70 with advanced, mid-stage HR-breast cancer treated or considered for multiagent chemotherapy according to recognized standards of care. These rates are computed based on data directly reported from CoC approved registries to the NCDB using specifications endorsed by the NQF. The CP3R provides cancer programs with the opportunity to examine data to determine if these performance rates are representative of the care provided at the institution. This application provides the ability to review and modify cases using this application. Simply click on the cell of underlined cases of interest to view a detailed case listing. Displayed performance rates are immediately updated once modifications via the CP3R are completed by cancer program staff. Note, any modifications made online should be reflected at the local cancer registry, and cancer programs are encouraged to resubmit data to the NCDB.
Page 1: Albert J. and Judith A. Dunlap Canc
Page 5 and 6: Daniel Burns, M.D., Cancer Committe
Page 7 and 8: At CHAMPS Oncology, the emphasis is
Page 9 and 10: Mayo Clinic Health System in Eau Cl

Albert J. and Judith A. Dunlap Cancer Center at Mayo Clinic Health ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?